Hepatoma Research Sees Steady Growth: 2024 CiteScore Rises to 3.5!
On June 3, 2025, Scopus released the 2024 CiteScore metrics. Hepatoma Research is pleased to report a continued rise in its score, reaching 3.5, up from 3.2 in 2023. This steady upward reflects the journal’s growing academic influence and its ongoing commitment to publishing high-quality, impactful research in the field of liver cancer. The CiteScore, calculated by Elsevier’s Scopus database, represents the average number of citations received per document over a four-year period. It is widely regarded as a key indicator of a journal’s impact, relevance, and standing in the global research community.
This achievement underscores the growing recognition of Hepatoma Research within the hepatology and oncology fields. We sincerely thank our authors, reviewers, and Editorial Board members for their invaluable support and contributions. Your dedication continues to drive the journal’s success.
Hepatoma Research remains firmly dedicated to advancing liver cancer research and promoting global scientific exchange. We look forward to continuing our collaboration with researchers worldwide to further elevate the journal’s influence and support future breakthroughs in the field.
Editor’s Picks: Highly Cited Articles (2023-2024):
1. Issue on combined locoregional and systemic treatment for hepatocellular carcinoma
Authors: Yi-Chia (Jasmine) Wu, Ali Wakil, Fayssa Salomon, Nikolaos Pyrsopoulos
2. Barriers to surveillance for hepatocellular cancer among patients with chronic liver disease -providers’ perspectives
Authors: Eliza W. Beal, Leva Gorji, Jaclyn Volney, Lindsey Sova, Ann Scheck McAlearney, Allan Tsung
3. Ultrasonography in surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
Authors: Theresa J. Hydes, Daniel J. Cuthbertson, Daniel H. Palmer, Omar Elshaarawy, Philip J. Johnson, Rashika Fernando, Timothy J. Cross
4. Challenges and barriers in hepatocellular carcinoma (HCC) surveillance for patients with non-alcoholic fatty liver disease (NAFLD)
Authors: Kara Wegermann, Anna Mae Diehl, Cynthia A. Moylan
5. The role of tumor microenvironment in cholangiocarcinoma
Authors: Maria Eva Argenziano, Michele Montori, Chiara Scorzoni, Antonio Benedetti, Marco Marzioni, Luca Maroni
6. Cholangiocarcinoma tumor microenvironment highlighting fibrosis and matrix components
Authors: Alessandra Caligiuri, Maurizio Parola, Fabio Marra, Stefania Cannito, Alessandra Gentilini
7. Targeting the interactions between lymphocytes and liver cancer stem cells in combination with immunotherapy is a promising therapeutic strategy
Authors: Wo-Ming Chen, Xiao-Ping Zhang, Yuan-Yuan Yan, Xiao Sun, Lei Li
8. Signaling and molecular networks related to development and inflammation involved in CCA initiation and progression
Authors: Antonio Cigliano, Alastair J. Strain, Massimiliano Cadamuro
9. Expression and function of collagens in intrahepatic cholangiocarcinoma
Authors: Tania Colasanti, Helin Vakifahmetoglu-Norberg, Carmine Mancone
10. Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward?
Authors: Cristina Dopazo, Ramón Charco
11. Current landscape and future directions for systemic treatments of hepatocellular carcinoma
Authors: Leonardo G. Fonseca, Flair J. Carrilho
12. Ethnic disparities in the epidemiology, treatment, and outcome of patients with hepatocellular carcinoma in the United States
Authors: Mohammad Saeid Rezaee-Zavareh, Jeff Liang, Ju Dong Yang
13. Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease
Authors: Carmen Colaci, Maria Luisa Gambardella, Giuseppe Guido Maria Scarlata, Luigi Boccuto, Carmela Colica, Francesco Luzza, Emidio Scarpellini, Nahum Mendez-Sanchez, Ludovico Abenavoli
14. Is the Mediterranean diet a good preventive measure for NASH?
Authors: Anna Caterina Procopio, Maria Rosaria Paravati, Giuseppe Guido Maria Scarlata, Maddalena Parafati, Natasa Milić, Francesco Luzza, Ludovico Abenavoli
15. The role of immune checkpoint inhibitors and/or Yttrium-90 radioembolization in the management of hepatocellular carcinoma: challenges of treatment sequence
Authors: Samantha M. Ruff, Timothy M. Pawlik
16. Impact of diet and gut microbiota changes in the development of hepatocellular carcinoma
Authors: Giuseppe Guido Maria Scarlata, Claudia Cicino, Rocco Spagnuolo, Nadia Marascio, Angela Quirino, Giovanni Matera, Dan Lucian Dumitrașcu, Francesco Luzza, Ludovico Abenavoli
Explore the journal and access the latest articles: Hepatoma Research
Editor: Weiwei Yan
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully submitted by the Editorial Office of Hepatoma Research
